AI and MRIs at birth can predict cognitive development at age two, study finds

Medical Xpress | March 15, 2019

Researchers at the University of North Carolina School of Medicine used MRI brain scans and machine learning techniques at birth to predict cognitive development at age 2 years with 95 percent accuracy.
"This prediction could help identify children at risk for poor cognitive development shortly after birth with high accuracy," said senior author John H. Gilmore, MD, Thad and Alice Eure Distinguished Professor of psychiatry and director of the UNC Center for Excellence in Community Mental Health. "For these children, an early intervention in the first year or so of life when cognitive development is happening could help improve outcomes. For example, in premature infants who are at risk, one could use imaging to see who could have problems." The study, which was published online by the journal NeuroImage, used an application of artificial intelligence called machine learning to look at white matter connections in the brain at birth and the ability of these connections to predict cognitive outcomes.

Spotlight

Spotlight

Related News

Cell and Gene Therapy

Ceres Nanosciences and Ginkgo Bioworks Partner to Bring Pathogen Monitoring Capabilities to Labs Around the World

prnewswire | September 14, 2023

Ceres Nanosciences, a global leader in developing wastewater testing methods based on its Nanotrap® technology, and Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity, today announced that they are partnering to bring pathogen monitoring capabilities to laboratories around the world. Pathogen monitoring and analysis capabilities, including in wastewater, are designed to help public health institutions address regional biosecurity challenges. Supported by the NIH RADx Initiative, Ceres developed their Nanotrap technology for robust, sensitive, and time-saving methods to detect a wide range of pathogens in wastewater samples and has deployed those methods to a network of testing sites in the United States. These sites provide wastewater testing services nationwide to deliver valuable public health data, such as information about the relative abundance of COVID-19 variant groups over time in a community's wastewater, to the CDC's National Wastewater Surveillance System and to state, local, and Tribal decision makers. Recently, Concentric by Ginkgo, the biosecurity unit of Ginkgo Bioworks, as part of a CDC program, demonstrated in a study with partners from XPresCheck and Louisiana State University that coupling Ceres' aircraft wastewater testing methods with Concentric's analysis can enable early detection of variants of SARS-CoV-2. San Francisco International Airport was the first airport to announce that it will continuously monitor airplane wastewater samples as part of a CDC program operated by Concentric and XpresCheck. Under the partnership between Ceres and Concentric, labs in countries where Concentric has biosecurity programs receive on-site training and the materials needed to implement the standardized and proven wastewater testing workflow from Ceres. Labs also receive biosecurity tools and data infrastructure to leverage automation, data analysis, bioinformatics capabilities, and other critical genomic sequencing technologies. Together, Ceres and Concentric have set up labs in the Middle East and Africa through this collaboration, offering a cutting-edge approach to biosurveillance technologies and capacity building for labs around the world that are part of Concentric's global pathogen monitoring network. "Under our NIH RADx Initiative, we demonstrated that we can quickly stand up improved wastewater testing capabilities for labs that are experts or novices in the space," said Robbie Barbero, Chief Business Officer at Ceres Nanosciences. "We are delighted now to be partnering with a global leader like Concentric to build a robust public health framework worldwide." "Ceres Nanosciences has been a terrific partner in developing effective and innovative methods for identifying pathogens in wastewater," said Matt McKnight, General Manager, Biosecurity at Ginkgo Bioworks. "By combining their laboratory expertise with our global footprint, we are building a robust global biological radar to prevent, detect, and respond to biological threats." About Ceres Nanosciences, Inc. Ceres Nanosciences is a privately held company, located in Northern Virginia, focused on incorporating its proprietary Nanotrap® particle technology into a range of diagnostic and research use products and workflows. Nanotrap particles capture, concentrate, and preserve low abundance analytes from biological samples, enabling early and accurate detection of diseases. The Nanotrap particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, the Centers for Disease Control and Prevention, and the Commonwealth of Virginia. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats.

Read More

Medical

SQZ Biotechnologies Provides Update on Collaboration with Roche

Businesswire | July 26, 2023

SQZ Biotechnologies Company announced that Roche has determined that it will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program. SQZ Biotechnologies will regain full clinical development and future commercialization rights for its programs targeting HPV 16 positive tumors. The Company intends to explore potential strategic partnerships to support the advancement of its oncology programs and platforms. The Company has completed a review of its portfolio and highlights the following achievements. SQZ® antigen presenting cells (APC) candidate was well tolerated in a Phase 1 trial and provided a significant survival benefit to a subpopulation of patients with enhanced tumor T cell infiltration. SQZ® enhanced antigen presenting cells (eAPC) candidate has completed enrollment of the highest dose monotherapy cohort in a Phase 1/2 trial, and initial data are anticipated in the second half of 2023. In addition, the low dose monotherapy cohort from the Phase 1 trial utilizing the Company’s Activating Antigen Carriers (AAC) candidate has demonstrated a confirmed complete response in one patient and an overall best response of stable disease in the other two patients. The high dose monotherapy cohort in this trial is currently enrolling, and initial data are anticipated in the fourth quarter of 2023. Finally, development and testing of the Point of Care Manufacturing system continue to advance and could significantly reduce the time and cost of cell therapy manufacturing and potentially make cell therapies more broadly accessible for patients. “We have made meaningful progress across all our platforms this year and the management team and Board of Directors are enthusiastic about the power of Cell Squeeze® technology and the potential of the Company’s therapeutic programs,” said Howard Bernstein, Interim CEO and Member of the Board of Directors at SQZ. “As we move into the second half of this year, we are committed to assessing all of the Company’s potential strategic alternatives in an effort to advance our programs.” About SQZ Biotechnologies SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies. The Company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what the Company believes can be a broad range of potential therapeutics. The Company’s goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, the Company believes its approach could change the way people think about cell therapies.

Read More

Medical, Industry Outlook

Introducing the Anbio ADL i1910: An Elegant CLIA Analyzer for Comprehensive Clinical Testing

PRNewswire | July 12, 2023

Anbio, a leading provider of innovative diagnostic solutions, proudly presents the Anbio ADL i1910, a fully automated, compact, and affordable CLIA analyzer designed to transform the landscape of clinical diagnostics. With its cutting-edge technology and versatile capabilities, the ADL i1910 offers a comprehensive range of qualitative and quantitative testing options for analytes in human serum, plasma, whole blood, and urine samples. The ADL i1910 utilizes a direct chemiluminescence method based on acridinium ester, ensuring accurate and reliable results across a wide array of applications. Whether it's hormone detection, myocardial disease screening, infectious disease diagnostics, or tumor-related antigen analysis, the ADL i1910 delivers exceptional performance and meets the diverse needs of modern healthcare professionals. Key Features of the Anbio ADL i1910 Extensive Assay Menu: The ADL i1910 boasts an impressive range of 49 developed assays, allowing for both qualitative and quantitative testing of analytes. This comprehensive immunodiagnostic solution enables healthcare providers to access critical information efficiently. High Throughput: With a remarkable throughput of up to 120 tests per hour, the ADL i1910 significantly enhances laboratory productivity. Rapid turnaround times enable healthcare providers to make timely and informed decisions, ultimately improving patient care. Compact Footprint: Anbio understands the importance of laboratory space. The ADL i1910 has been meticulously designed to occupy minimal space, making it suitable for laboratories of all sizes. Its small footprint ensures that valuable space can be optimized for other essential equipment. User-Friendly Interface: The ADL i1910 features an intuitive graphic user interface with a large color touch screen, simplifying operation and minimizing the learning curve. The user-friendly design ensures ease of use for both experienced professionals and new users, enhancing overall efficiency. "Anbio is proud to introduce the ADL i1910, a breakthrough CLIA analyzer that revolutionizes clinical diagnostics," said Jack Davis, Chief Business Officer at Anbio. "With its advanced technology, extensive assay menu, and impressive throughput, the ADL i1910 provides healthcare professionals with a reliable and efficient solution for a wide range of diagnostic applications." The Anbio ADL i1910 is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution. About Anbio Biotechnology Anbio Biotechnology is devoted to making contributions for human health and has never stopped our goal to innovate in life sciences. Driven by continuous technical development and integration, resulting from close cooperation with prestigious institutes across the world. Anbio always strives to provide total solutions in clinical diagnosis field, by offering extensive diagnostic products including laboratory and point-of-care products.

Read More